<DOC>
	<DOCNO>NCT00033553</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Computer system allow doctor create 3-dimensional picture tumor plan treatment may result effective radiation therapy . It yet know chemotherapy and/or radiation therapy regimen effective treat non-small cell lung cancer . PURPOSE : Randomized phase II trial compare effectiveness different combination chemotherapy regimens 3-dimensional radiation therapy treat patient unresectable stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Computer-Planned Radiation Therapy Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall response rate , failure-free survival , survival patient inoperable stage IIIA IIIB non-small cell lung cancer treat paclitaxel carboplatin concurrent 3-dimensional conformal radiotherapy ( 3-D XRT ) v gemcitabine carboplatin concurrent 3-D XRT . - Compare toxicity regimens patient . - Compare pattern failure ( locoregional v distant failure ) patient treat regimen . - Determine feasibility deliver 3-D XRT patient multicenter study . OUTLINE : This randomize , multicenter study . Patients randomize one two treatment arm . - Arm I : Patients receive paclitaxel IV 3 hour follow carboplatin IV 30 minute day 1 . Treatment repeat every 21 day 2 course . Patients receive paclitaxel IV 1 hour follow carboplatin IV 30 minute weekly 3-dimensional conformal radiotherapy ( 3-D XRT ) daily 5 day week . Treatment repeat weekly 7 course . - Arm II : Patients receive gemcitabine IV 30 minute day 1 8 follow carboplatin IV 30 minute day 1 . Treatment repeat every 21 day 2 course . Patients receive gemcitabine IV 30 minute twice weekly 3-D XRT arm I . Treatment repeat weekly 7 course . In arm , treatment continue absence disease progression . Patients follow every 2 month 2 year , every 4 month 2 year , annually 2 year . PROJECTED ACCRUAL : A total 82 patient ( 41 per treatment arm ) accrue study within 9 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) Squamous cell carcinoma Adenocarcinoma , include bronchoalveolar cell carcinoma Large cell anaplastic carcinoma , include giant clear cell carcinoma Inoperable stage IIIA IIIB disease No direct invasion vertebral body Tumors adjacent vertebral body without bone invasion allow gross disease encompass radiotherapy boost field Contralateral mediastinal disease ( N3 ) allow gross disease encompass radiotherapy boost field No scalene , supraclavicular , contralateral hilar node involvement Transudate , cytologically negative , nonbloody pleural effusion allow encompassed radiotherapy field No exudative , bloody , cytologically malignant pleural effusion Evidence pleural effusion chest CT scan chest xray small tap allow At least 1 unidimensionally measurable lesion At least 20 mm conventional technique OR At least 10 mm spiral CT scan The following consider measurable disease : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Abdominal mass confirm followed imaging technique Cystic lesion Tumor lesion previously irradiate field PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL AST le 2 time upper limit normal Renal : Creatinine clearance 20130 mL/min female Creatinine clearance 20150 mL/min male Pulmonary : FEV1 least 1.2 L Other : Not pregnant nursing Fertile patient must use effective contraception No currently active malignancy ( define complete prior therapy consider less 30 % risk relapse ) except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy NSCLC No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy except steroid adrenal failure septic shock , hormone nondiseaserelated condition ( e.g. , insulin diabetes ) , glucocorticosteroids antiemetic Radiotherapy : See Disease Characteristics No prior radiotherapy NSCLC Surgery : At least 2 week since prior exploratory thoracotomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
</DOC>